Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Fundamental Analysis

NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD

2.21  +0.05 (+2.31%)

After market: 2.22 +0.01 (+0.45%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to GANX. GANX was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of GANX have multiple concerns. GANX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GANX had negative earnings in the past year.
In the past year GANX has reported a negative cash flow from operations.
In the past 5 years GANX always reported negative net income.
GANX had a negative operating cash flow in each of the past 5 years.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -148.74%, GANX is not doing good in the industry: 84.42% of the companies in the same industry are doing better.
GANX's Return On Equity of -239.83% is on the low side compared to the rest of the industry. GANX is outperformed by 70.97% of its industry peers.
Industry RankSector Rank
ROA -148.74%
ROE -239.83%
ROIC N/A
ROA(3y)-76.09%
ROA(5y)-119.48%
ROE(3y)-103.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

2

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GANX has more shares outstanding than it did 1 year ago.
GANX has a worse debt/assets ratio than last year.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

GANX has an Altman-Z score of -5.54. This is a bad value and indicates that GANX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.54, GANX is not doing good in the industry: 64.25% of the companies in the same industry are doing better.
GANX has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
GANX's Debt to Equity ratio of 0.04 is on the low side compared to the rest of the industry. GANX is outperformed by 61.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -5.54
ROIC/WACCN/A
WACC10.72%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

GANX has a Current Ratio of 2.99. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a worse Current ratio (2.99) than 65.84% of its industry peers.
A Quick Ratio of 2.99 indicates that GANX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.99, GANX is not doing good in the industry: 63.36% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.99
Quick Ratio 2.99
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

GANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.36%, which is quite impressive.
Looking at the last year, GANX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, GANX shows a very strong growth in Revenue. The Revenue has been growing by 22.50% on average per year.
EPS 1Y (TTM)35.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.05%
Revenue 1Y (TTM)-100%
Revenue growth 3Y22.52%
Revenue growth 5Y22.5%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GANX will show a decrease in Earnings Per Share. The EPS will decrease by -4.16% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y43.65%
EPS Next 2Y23.84%
EPS Next 3Y9.32%
EPS Next 5Y-4.16%
Revenue Next Year-100%
Revenue Next 2Y-60.03%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.84%
EPS Next 3Y9.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GANX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (2/4/2025, 4:11:17 PM)

After market: 2.22 +0.01 (+0.45%)

2.21

+0.05 (+2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners11.92%
Inst Owner Change-25.29%
Ins Owners5.09%
Ins Owner Change15.89%
Market Cap57.37M
Analysts85
Price Target7.48 (238.46%)
Short Float %1.52%
Short Ratio1.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.7%
Min EPS beat(2)-105.88%
Max EPS beat(2)22.48%
EPS beat(4)2
Avg EPS beat(4)-16.64%
Min EPS beat(4)-105.88%
Max EPS beat(4)26.26%
EPS beat(8)3
Avg EPS beat(8)-19.26%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.64%
EPS NQ rev (1m)4.76%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)6.57%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.44
P/tB 6.55
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.74%
ROE -239.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.09%
ROA(5y)-119.48%
ROE(3y)-103.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.99
Quick Ratio 2.99
Altman-Z -5.54
F-Score4
WACC10.72%
ROIC/WACCN/A
Cap/Depr(3y)222.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)56.6%
Cap/Sales(5y)52.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.05%
EPS Next Y43.65%
EPS Next 2Y23.84%
EPS Next 3Y9.32%
EPS Next 5Y-4.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y22.52%
Revenue growth 5Y22.5%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-60.03%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y4.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.09%
OCF growth 3YN/A
OCF growth 5YN/A